Committee considers updating law to let schools stock FDA‑approved nasal epinephrine

Summary

LB1217 would let Nebraska schools carry FDA‑approved epinephrine in any form (including newly approved nasal spray) as emergency stock. Medical and nursing groups told senators nasal epinephrine can be needle‑free, easier to administer and has a longer shelf life than injectables; committee discussion focused on implementation and consent procedures.

Senator Brian Hardin introduced LB1217, a statutory update to allow schools to maintain emergency stock epinephrine in any form approved by the Food and Drug Administration, including nasal epinephrine products approved since 2024.

Holly Dingman of Children's Nebraska testified the nasal option offers needle‑free administration, rapid absorption and a longer shelf life, and that school health staff frequently face allergic reactions that occur without prior diagnosis. The Nebraska Nurses Association urged the committee to adopt the change, emphasizing the time‑sensitive nature of anaphylaxis and the practical advantages of a product that reduces training steps and needle‑handling in schools.

Committee members asked whether new consent rules or parental notification would be needed; witnesses said LB1217 simply authorizes schools to stock additional FDA‑approved forms and that existing school emergency‑care legal frameworks would govern administration in emergencies. The hearing drew broad support with no opponents testifying in person.